Lung cancer survival breakthrough
Ivonescimab reduces death risk by 27% compared to pembrolizumab in lung cancer trial.
Anonymous
Key Points
1
At two and three years, overall survival rates were 57.9% versus 48.0% and 45.0% versus 33.1% for ivonescimab and pembrolizumab, respectively, showing that the survival separation widened with longer follow-up.
2
HARMONi-2 enrolled treatment-naive patients with locally advanced or metastatic NSCLC whose PD-L1 tumor proportion score was at least 1% and who had no EGFR or ALK alterations. Patients were randomized to ivonescimab 20 mg/kg (198 patients) or pembrolizumab 200 mg (200 patients) every three weeks at Chinese centers.
3
The overall-survival analysis was based on 234 deaths at the August 20, 2026, data cutoff, after a median follow-up of about 36 months; the prespecified result crossed the trial’s O’Brien-Fleming significance boundary.
4
The squamous-disease population included patients with bleeding-risk features that have historically limited use of conventional anti-VEGF drugs: 72.2% had centrally located tumors, 10% had cavitation or necrosis, and 6.7% had major-vessel encasement. Ivonescimab showed no apparent increase in bleeding, although HARMONi-2 was not powered to formally test that safety question.
Ivonescimab cut the death risk by 27% in patients with advanced lung cancer compared to pembrolizumab, according to results from the HARMONi-2 trial presented at the 2026 World Conference on Lung Cancer Nasdaq. Among 398 Chinese patients, those who received ivonescimab survived a median of 30.8 months versus 22.6 months for pembrolizumab — a meaningful gain for a common and deadly cancer type RTT News.
The drug showed particular promise in patients whose tumors had high PD-L1 expression. At three years, 45% of ivonescimab patients were still alive compared to 33% on pembrolizumab Nasdaq. Ivonescimab is already approved in China for this use, but researchers are still testing it in other countries to see if the results hold globally.
A 27% Survival Boost in the HARMONi-2 Trial
The HARMONi-2 study enrolled 398 treatment-naive patients in China with advanced lung cancer and no EGFR or ALK gene mutations Nasdaq. Patients received either ivonescimab (198 patients) or pembrolizumab (200 patients) every three weeks RTT News. The survival analysis tracked 234 deaths over about 36 months of follow-up.
Ivonescimab patients had a median overall survival of 30.8 months versus 22.6 months with pembrolizumab — representing a 27% reduction in death risk Nasdaq. The benefit grew over time. At two years, 57.9% of ivonescimab patients survived compared to 48% on pembrolizumab; at three years, that gap widened to 45% versus 33% RTT News.
Progression-Free Survival Roughly Doubles With Ivonescimab
Before tumors started growing again, ivonescimab patients gained extra time. Median progression-free survival was 11.1 months with ivonescimab compared to 5.8 months with pembrolizumab Nasdaq. This earlier benefit in slowing tumor growth preceded the overall survival advantage, suggesting the drug was working to control cancer earlier in treatment.
The survival benefit held up across both squamous and nonsquamous lung cancer types Nasdaq. Patients with higher PD-L1 expression — a marker that predicts immunotherapy response — saw particularly strong results. Squamous cancers are harder to treat and have historically limited treatment options.
Squamous Tumors Show No Bleeding Risk From Ivonescimab
Squamous lung cancers in high-risk patients often cannot safely receive anti-VEGF drugs because those medications increase bleeding. In HARMONi-2, 72.2% of squamous patients had centrally located tumors, 10% had cavitation or necrosis, and 6.7% had major-vessel encasement — features that typically raise bleeding danger RTT News.
Despite these high-risk features, ivonescimab showed no apparent increase in bleeding events RTT News. The trial was not powered to formally prove safety, so more data from global studies will be needed. This finding could expand treatment options for squamous patients who currently have few choices beyond traditional chemotherapy.
Global Trial Data Needed to Confirm Broader Applicability
HARMONi-2 was conducted entirely in China, which means results may not directly apply to patients in other countries. Genetic differences, tumor biology, and access to supportive care vary globally Nasdaq. A separate global HARMONi trial is underway to test whether the 27% survival improvement holds in diverse patient populations worldwide.
Ivonescimab is already approved in China for first-line treatment of PD-L1-positive advanced lung cancer Nasdaq. International regulators will likely want to see data from the broader HARMONi study before making approval decisions. Researchers are also evaluating the drug's safety and efficacy in squamous tumors specifically, given the historical bleeding concerns with other immunotherapies.
Sentiment
Mostly PositiveNEGATIVENEUTRALPOSITIVE
Publishers
15
Articles
64
Reach
79
A
AnonymousAuthor
